Business Description
Roche Holding AG
NAICS : 325412
SIC : 2834
ISIN : CH0012032048
Description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.3 | |||||
| Equity-to-Asset | 0.31 | |||||
| Debt-to-Equity | 0.96 | |||||
| Debt-to-EBITDA | 1.33 | |||||
| Interest Coverage | 17.91 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.27 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.3 | |||||
| 3-Year EBITDA Growth Rate | 0.9 | |||||
| 3-Year EPS without NRI Growth Rate | -0.5 | |||||
| 3-Year FCF Growth Rate | -5.4 | |||||
| 3-Year Book Growth Rate | -2.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 3.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | 2.14 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.47 | |||||
| 9-Day RSI | 44.33 | |||||
| 14-Day RSI | 43.99 | |||||
| 6-1 Month Momentum % | -2.45 | |||||
| 12-1 Month Momentum % | -19.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.18 | |||||
| Quick Ratio | 0.86 | |||||
| Cash Ratio | 0.29 | |||||
| Days Inventory | 165.57 | |||||
| Days Sales Outstanding | 68.99 | |||||
| Days Payable | 77.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.71 | |||||
| Dividend Payout Ratio | 0.69 | |||||
| 3-Year Dividend Growth Rate | 2.2 | |||||
| Forward Dividend Yield % | 3.71 | |||||
| 5-Year Yield-on-Cost % | 4.24 | |||||
| 3-Year Average Share Buyback Ratio | 2.3 | |||||
| Shareholder Yield % | 5.97 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.9 | |||||
| Operating Margin % | 26.16 | |||||
| Net Margin % | 18.38 | |||||
| ROE % | 41.51 | |||||
| ROA % | 12.76 | |||||
| ROIC % | 17.39 | |||||
| ROC (Joel Greenblatt) % | 60.59 | |||||
| ROCE % | 25.88 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 18.69 | |||||
| Forward PE Ratio | 12.64 | |||||
| PE Ratio without NRI | 18.69 | |||||
| Shiller PE Ratio | 18.86 | |||||
| Price-to-Owner-Earnings | 16.52 | |||||
| PEG Ratio | 3.22 | |||||
| PS Ratio | 3.44 | |||||
| PB Ratio | 7.71 | |||||
| Price-to-Tangible-Book | 29.98 | |||||
| Price-to-Free-Cash-Flow | 16.31 | |||||
| Price-to-Operating-Cash-Flow | 12.03 | |||||
| EV-to-EBIT | 14.61 | |||||
| EV-to-Forward-EBIT | 10.58 | |||||
| EV-to-EBITDA | 11.78 | |||||
| EV-to-Forward-EBITDA | 9.05 | |||||
| EV-to-Revenue | 3.75 | |||||
| EV-to-Forward-Revenue | 3.58 | |||||
| EV-to-FCF | 17.78 | |||||
| Price-to-DCF (Earnings Based) | 1.62 | |||||
| Price-to-DCF (FCF Based) | 1.41 | |||||
| Price-to-Graham-Number | 4.99 | |||||
| Earnings Yield (Greenblatt) % | 6.84 | |||||
| Forward Rate of Return (Yacktman) % | 12.57 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Roche Holding AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 59,997 | ||
| EPS (TTM) (CHF) | 13.7 | ||
| Beta | 0.72 | ||
| Volatility % | 15.3 | ||
| 14-Day RSI | 43.99 | ||
| 14-Day ATR (CHF) | 3.905485 | ||
| 20-Day SMA (CHF) | 257.7775 | ||
| 12-1 Month Momentum % | -19.54 | ||
| 52-Week Range (CHF) | 249.8 - 335.85 | ||
| Shares Outstanding (Mil) | 798.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Roche Holding AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Roche Holding AG Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Roche Holding AG Frequently Asked Questions
What is Roche Holding AG(XSWX:ROG)'s stock price today?
The current price of XSWX:ROG is CHF256.10. The 52 week high of XSWX:ROG is CHF335.85 and 52 week low is CHF249.80.
When is next earnings date of Roche Holding AG(XSWX:ROG)?
The next earnings date of Roche Holding AG(XSWX:ROG) is 2024-02-02 Est..
Does Roche Holding AG(XSWX:ROG) pay dividends? If so, how much?
The Dividend Yield %  of Roche Holding AG(XSWX:ROG) is 3.71% (As of Today), Highest Dividend Payout Ratio of Roche Holding AG(XSWX:ROG) was 0.82. The lowest was 0.55. And the median was 0.64. The  Forward Dividend Yield % of Roche Holding AG(XSWX:ROG) is 3.71%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers